|Bid||8,066.00 x 0|
|Ask||8,067.00 x 0|
|Day's range||8,029.00 - 8,265.00|
|52-week range||6,499.80 - 8,848.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||38.67|
|Earnings date||12 Nov 2021|
|Forward dividend & yield||2.02 (2.49%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||N/A|
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. In particular, the results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective res
WILMINGTON, Del., September 17, 2021--Results from the large, randomized COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with IMFINZI® (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to IMFINZI alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).
In the past 10 years, the pharmaceutical industry's performance has lagged well behind that of the broader market. The SPDR S&P Pharmaceutical Index ETF, an industry benchmark, is up by 107% in the past decade, less than half what the S&P 500 has returned in the same period. It could be that investors are worried about a complete overhaul of the entire healthcare industry, which has been the goal of several prominent U.S. politicians.